Source:http://linkedlifedata.com/resource/pubmed/id/11436112
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2001-7-3
|
| pubmed:abstractText |
In a retrospective single center study, we examined the outcome of induced GVHD in leukemia patients relapsing after allogeneic BMT. Thirty-three adult patients with leukemia (15 AML, 3 ALL, and 15 CML) persisting or relapsing 1-36 months (median, 6) after allogeneic BMT underwent various immune manipulations and consequently developed acute and/or chronic GVHD at our center. Immunotherapies to elicit GVHD comprised chemotherapy followed by PBSC (n = 18), non-myeloablative transplant (n = 2), PBL followed by IFN-alpha (n = 5), PBL alone (n = 3), abrupt cessation of CsA (n = 3), and CsA withdrawal combined with IFN-alpha (n = 2). Twenty-four (72.7%) patients obtained a remission including complete hematological or cytogenetic remission, respectively, for acute leukemias or CML. Overall survival of patients, estimated at 3 years using the Kaplan-Meier method, was 33.9% (95% CI, 20-52%). Twelve patients including two patients with ALL remain in complete hematological (n = 5) or cytogenetic remission (n = 7) 3-93 months (median 12) after achieving remission. Twelve (63.2%) of 19 dead patients died due to treatment-related toxicities; five patients from acute GVHD, three from GVHD followed by infections and four from infections. By multivariate Cox analysis, only chronic GVHD resulted in a higher probability of disease-free survival (P = 0.026). Eight patients who had both acute GVHD < or = grade I and chronic GVHD are all alive without leukemia. We conclude that acute GVHD is associated with considerable toxicity while chronic GVHD plays a role in retaining remission in leukemia relapsing after allogeneic BMT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
999-1005
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11436112-Adolescent,
pubmed-meshheading:11436112-Adult,
pubmed-meshheading:11436112-Antineoplastic Agents,
pubmed-meshheading:11436112-Bone Marrow Transplantation,
pubmed-meshheading:11436112-Cyclosporine,
pubmed-meshheading:11436112-Female,
pubmed-meshheading:11436112-Graft vs Host Disease,
pubmed-meshheading:11436112-Graft vs Leukemia Effect,
pubmed-meshheading:11436112-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11436112-Humans,
pubmed-meshheading:11436112-Immunotherapy,
pubmed-meshheading:11436112-Interferon-alpha,
pubmed-meshheading:11436112-Leukemia,
pubmed-meshheading:11436112-Leukocyte Transfusion,
pubmed-meshheading:11436112-Male,
pubmed-meshheading:11436112-Recurrence,
pubmed-meshheading:11436112-Remission Induction,
pubmed-meshheading:11436112-Retrospective Studies,
pubmed-meshheading:11436112-Survival Rate,
pubmed-meshheading:11436112-Transplantation, Homologous
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
|
| pubmed:affiliation |
The Catholic Hemopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|